Cosmo Pharmaceuticals N.V
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more
Cosmo Pharmaceuticals N.V (CMOPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.002x
Based on the latest financial reports, Cosmo Pharmaceuticals N.V (CMOPF) has a cash flow conversion efficiency ratio of 0.002x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($900.00K) by net assets ($466.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cosmo Pharmaceuticals N.V - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Cosmo Pharmaceuticals N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cosmo Pharmaceuticals N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cosmo Pharmaceuticals N.V ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunan Jiudian Pharmaceutical Co Ltd
SHE:300705
|
0.068x |
|
Zhejiang Dayuan Pumps Ind Co
SHG:603757
|
-0.003x |
|
TES Co. Ltd
KQ:095610
|
0.030x |
|
Ovzon AB
ST:OVZON
|
0.079x |
|
ARGAN EO 2
F:871
|
N/A |
|
Shanxi Blue Flame Holding Co Ltd
SHE:000968
|
0.040x |
|
Gravita India Limited
NSE:GRAVITA
|
-0.022x |
|
Zhejiang Sunflower Light Energy
SHE:300111
|
0.003x |
Annual Cash Flow Conversion Efficiency for Cosmo Pharmaceuticals N.V (2004–2024)
The table below shows the annual cash flow conversion efficiency of Cosmo Pharmaceuticals N.V from 2004 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $505.09 Million | $162.41 Million | 0.322x | +507.52% |
| 2023-12-31 | $429.04 Million | $22.71 Million | 0.053x | -26.12% |
| 2022-12-31 | $463.79 Million | $33.23 Million | 0.072x | +191.24% |
| 2021-12-31 | $512.68 Million | $12.61 Million | 0.025x | -24.20% |
| 2020-12-31 | $400.12 Million | $12.98 Million | 0.032x | +167.80% |
| 2019-12-31 | $393.73 Million | $-18.85 Million | -0.048x | -109.50% |
| 2018-12-31 | $444.85 Million | $-10.16 Million | -0.023x | -7.32% |
| 2017-12-31 | $470.12 Million | $-10.01 Million | -0.021x | -133.50% |
| 2016-12-31 | $415.56 Million | $26.41 Million | 0.064x | +165.40% |
| 2015-12-31 | $403.65 Million | $-39.23 Million | -0.097x | -122.27% |
| 2014-12-31 | $152.29 Million | $66.45 Million | 0.436x | +1084.01% |
| 2013-12-31 | $220.16 Million | $8.11 Million | 0.037x | -80.04% |
| 2012-12-31 | $124.60 Million | $23.00 Million | 0.185x | +3.72% |
| 2011-12-31 | $63.43 Million | $11.29 Million | 0.178x | +33.42% |
| 2010-12-31 | $58.37 Million | $7.79 Million | 0.133x | +105.80% |
| 2009-12-31 | $59.80 Million | $3.88 Million | 0.065x | +122.39% |
| 2008-12-31 | $43.24 Million | $-12.52 Million | -0.290x | -303.62% |
| 2007-12-31 | $35.15 Million | $-2.52 Million | -0.072x | -106.31% |
| 2006-12-31 | $5.34 Million | $6.08 Million | 1.137x | -57.78% |
| 2005-12-31 | $631.00K | $1.70 Million | 2.694x | +1008.37% |
| 2004-12-31 | $-880.00K | $261.00K | -0.297x | -- |